Emergent Biosolutions (EBS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2005 | 12-2004 | |
| Cash Flows From Operating Activities | ||
| Net Income | 15,784 | 11,472 |
| Depreciation Amortization | 3,549 | 1,867 |
| Income taxes - deferred | -10,968 | -418 |
| Accounts receivable | 16,107 | -15,664 |
| Accounts payable and accrued liabilities | 5,463 | 2,472 |
| Other Working Capital | 33,870 | -4,409 |
| Other Operating Activity | -21,555 | 13,876 |
| Operating Cash Flow | $42,250 | $9,196 |
| Cash Flows From Investing Activities | ||
| Change In Deposits | N/A | 147 |
| PPE Investments | -6,532 | -17,072 |
| Net Acquisitions | -559 | N/A |
| Other Investing Activity | 0 | -1,250 |
| Investing Cash Flow | $-7,091 | $-18,175 |
| Cash Flows From Financing Activities | ||
| Change In Short Term Borrowing | 123 | 947 |
| Debt Issued | 31 | 10,992 |
| Debt Repayment | -1,110 | -2,535 |
| Common Stock Issued | 33 | 12 |
| Common Stock Repurchased | -337 | -665 |
| Dividend Paid | -5,400 | N/A |
| Other Financing Activity | 1,250 | -70 |
| Financing Cash Flow | $-5,410 | $8,681 |
| Exchange Rate Effect | -276 | N/A |
| Beginning Cash Position | 6,821 | 7,119 |
| End Cash Position | 36,294 | 6,821 |
| Net Cash Flow | $29,473 | $-298 |
| Free Cash Flow | ||
| Operating Cash Flow | 42,250 | 9,196 |
| Capital Expenditure | -6,532 | -17,072 |
| Free Cash Flow | 35,718 | -7,876 |